Alpha-1 antagonist treatment for eyelid retraction in patients with thyroid eye disease-a prospective pilot study
Sympathetic overstimulation of Müller's muscle is a suggested mechanism underlying upper eyelid retraction in thyroid eye disease (TED). We examined the effect of tamsulosin, an alpha-1 antagonist, on eyelid retraction in patients with TED. A single-centre prospective study. Patients with TED a...
Uloženo v:
| Vydáno v: | Eye (London) Ročník 39; číslo 1; s. 175 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.01.2025
|
| Témata: | |
| ISSN: | 1476-5454, 1476-5454 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Sympathetic overstimulation of Müller's muscle is a suggested mechanism underlying upper eyelid retraction in thyroid eye disease (TED). We examined the effect of tamsulosin, an alpha-1 antagonist, on eyelid retraction in patients with TED.
A single-centre prospective study. Patients with TED and associated eyelid retraction were treated with oral 0.4 mg/day tamsulosin for 3 months. Upper eyelid margins-to-reflex distance (MRD1), vertical palpebral fissure height (PFH), subjective improvement, signs and symptoms of dry eye, and lubricants use were assessed at baseline and at each subsequent visit.
Eleven suitable patients (mean age 47.5 ± 9.68, 8 females) enrolled in the study. Three patients discontinued the drug due to mild adverse effects (dizziness, bradycardia, nausea, and gastrointestinal distress), which resolved immediately upon stopping treatment. The other eight patients tolerated the drug well and reported no side effects. Five patients experienced an objective improvement in eyelid position and subjective improvement in eye discomfort. The mean MRD1 decreased by -1.04 ± 0.81 mm (P = 0.015), and mean PFH decreased by -1.46 ± 1.33 mm (P = 0.039). Mean duration of tamsulosin treatment was 84.63 ± 71.9 days. Patients discontinued the drug due to no improvement in MRD1 (n = 3), referral for eyelid surgery with stable inactive TED (n = 2), treatment with intravenous methylprednisolone due to worsening active TED (n = 2), and patient choice after 5 months of treatment with spontaneous resolution of symptoms (n = 1).
Tamsulosin is a safe potential treatment for eyelid retraction in TED and can be used as a temporary alternative therapeutic approach for patients unsuitable for surgery. |
|---|---|
| AbstractList | Sympathetic overstimulation of Müller's muscle is a suggested mechanism underlying upper eyelid retraction in thyroid eye disease (TED). We examined the effect of tamsulosin, an alpha-1 antagonist, on eyelid retraction in patients with TED.
A single-centre prospective study. Patients with TED and associated eyelid retraction were treated with oral 0.4 mg/day tamsulosin for 3 months. Upper eyelid margins-to-reflex distance (MRD1), vertical palpebral fissure height (PFH), subjective improvement, signs and symptoms of dry eye, and lubricants use were assessed at baseline and at each subsequent visit.
Eleven suitable patients (mean age 47.5 ± 9.68, 8 females) enrolled in the study. Three patients discontinued the drug due to mild adverse effects (dizziness, bradycardia, nausea, and gastrointestinal distress), which resolved immediately upon stopping treatment. The other eight patients tolerated the drug well and reported no side effects. Five patients experienced an objective improvement in eyelid position and subjective improvement in eye discomfort. The mean MRD1 decreased by -1.04 ± 0.81 mm (P = 0.015), and mean PFH decreased by -1.46 ± 1.33 mm (P = 0.039). Mean duration of tamsulosin treatment was 84.63 ± 71.9 days. Patients discontinued the drug due to no improvement in MRD1 (n = 3), referral for eyelid surgery with stable inactive TED (n = 2), treatment with intravenous methylprednisolone due to worsening active TED (n = 2), and patient choice after 5 months of treatment with spontaneous resolution of symptoms (n = 1).
Tamsulosin is a safe potential treatment for eyelid retraction in TED and can be used as a temporary alternative therapeutic approach for patients unsuitable for surgery. Sympathetic overstimulation of Müller's muscle is a suggested mechanism underlying upper eyelid retraction in thyroid eye disease (TED). We examined the effect of tamsulosin, an alpha-1 antagonist, on eyelid retraction in patients with TED.BACKGROUNDSympathetic overstimulation of Müller's muscle is a suggested mechanism underlying upper eyelid retraction in thyroid eye disease (TED). We examined the effect of tamsulosin, an alpha-1 antagonist, on eyelid retraction in patients with TED.A single-centre prospective study. Patients with TED and associated eyelid retraction were treated with oral 0.4 mg/day tamsulosin for 3 months. Upper eyelid margins-to-reflex distance (MRD1), vertical palpebral fissure height (PFH), subjective improvement, signs and symptoms of dry eye, and lubricants use were assessed at baseline and at each subsequent visit.METHODSA single-centre prospective study. Patients with TED and associated eyelid retraction were treated with oral 0.4 mg/day tamsulosin for 3 months. Upper eyelid margins-to-reflex distance (MRD1), vertical palpebral fissure height (PFH), subjective improvement, signs and symptoms of dry eye, and lubricants use were assessed at baseline and at each subsequent visit.Eleven suitable patients (mean age 47.5 ± 9.68, 8 females) enrolled in the study. Three patients discontinued the drug due to mild adverse effects (dizziness, bradycardia, nausea, and gastrointestinal distress), which resolved immediately upon stopping treatment. The other eight patients tolerated the drug well and reported no side effects. Five patients experienced an objective improvement in eyelid position and subjective improvement in eye discomfort. The mean MRD1 decreased by -1.04 ± 0.81 mm (P = 0.015), and mean PFH decreased by -1.46 ± 1.33 mm (P = 0.039). Mean duration of tamsulosin treatment was 84.63 ± 71.9 days. Patients discontinued the drug due to no improvement in MRD1 (n = 3), referral for eyelid surgery with stable inactive TED (n = 2), treatment with intravenous methylprednisolone due to worsening active TED (n = 2), and patient choice after 5 months of treatment with spontaneous resolution of symptoms (n = 1).RESULTSEleven suitable patients (mean age 47.5 ± 9.68, 8 females) enrolled in the study. Three patients discontinued the drug due to mild adverse effects (dizziness, bradycardia, nausea, and gastrointestinal distress), which resolved immediately upon stopping treatment. The other eight patients tolerated the drug well and reported no side effects. Five patients experienced an objective improvement in eyelid position and subjective improvement in eye discomfort. The mean MRD1 decreased by -1.04 ± 0.81 mm (P = 0.015), and mean PFH decreased by -1.46 ± 1.33 mm (P = 0.039). Mean duration of tamsulosin treatment was 84.63 ± 71.9 days. Patients discontinued the drug due to no improvement in MRD1 (n = 3), referral for eyelid surgery with stable inactive TED (n = 2), treatment with intravenous methylprednisolone due to worsening active TED (n = 2), and patient choice after 5 months of treatment with spontaneous resolution of symptoms (n = 1).Tamsulosin is a safe potential treatment for eyelid retraction in TED and can be used as a temporary alternative therapeutic approach for patients unsuitable for surgery.CONCLUSIONSTamsulosin is a safe potential treatment for eyelid retraction in TED and can be used as a temporary alternative therapeutic approach for patients unsuitable for surgery. |
| Author | Arnon, Roee Priel, Ayelet Landau-Prat, Daphna Cukierman-Yaffe, Tali Agmon-Levin, Nancy Sagiv, Oded Zloto, Ofira Goldberg, Hila Ben-Simon, Guy J |
| Author_xml | – sequence: 1 givenname: Roee orcidid: 0000-0001-9995-8574 surname: Arnon fullname: Arnon, Roee organization: Ophthalmology Department, Assuta Ashdod Hospital, Ashdod, Israel – sequence: 2 givenname: Hila orcidid: 0000-0002-6062-1066 surname: Goldberg fullname: Goldberg, Hila organization: The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel, Affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel – sequence: 3 givenname: Guy J orcidid: 0000-0002-3967-2694 surname: Ben-Simon fullname: Ben-Simon, Guy J organization: The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel, Affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel – sequence: 4 givenname: Ayelet surname: Priel fullname: Priel, Ayelet organization: The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel, Affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel – sequence: 5 givenname: Ofira orcidid: 0000-0002-3548-424X surname: Zloto fullname: Zloto, Ofira organization: The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel, Affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel – sequence: 6 givenname: Daphna orcidid: 0000-0002-0910-3829 surname: Landau-Prat fullname: Landau-Prat, Daphna organization: The Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel, Affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel – sequence: 7 givenname: Tali surname: Cukierman-Yaffe fullname: Cukierman-Yaffe, Tali organization: The Endocrinology Institute, Sheba Medical Center, Tel Hashomer, Israel, Affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel – sequence: 8 givenname: Nancy surname: Agmon-Levin fullname: Agmon-Levin, Nancy organization: The Clinical Immunology, Angioedema and Allergy Unit, The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel, Affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel – sequence: 9 givenname: Oded orcidid: 0000-0003-0563-278X surname: Sagiv fullname: Sagiv, Oded email: osagiv@mdanderson.org, osagiv@mdanderson.org organization: Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. osagiv@mdanderson.org |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39428445$$D View this record in MEDLINE/PubMed |
| BookMark | eNpN0E1rwzAMBmAzOtaP7Q_sMHzcxZsd2U1yLGVfUNil96AkyuqR2mnsbOTfL7AOdpIQj4R4l2zmvCPGbpV8UBKyx6CVBhAy0UKCliCyC7ZQOl0Lo42e_evnbBnCp5TTIJVXbA65TjKtzYKdNm13QKE4uogf3tkQeewJ45Fc5I3vOY3U2pr3FHusovWOW8c7jHYCgX_beODxMPZ-MhPltQ2EgQTyrveho2nli3hnWx95iEM9XrPLBttAN-e6Yvvnp_32VezeX962m52oIDVRZARpaiRAVeeyJATdVGDWKMtGVSbXgKZU60Q3QKnOqxQV1FktZaWlSQGTFbv_PTu9cRooxOJoQ0Vti478EApQKssgyXU20bszHcoj1UXX2yP2Y_GXUvIDQbZtRQ |
| CitedBy_id | crossref_primary_10_1038_s41433_024_03552_w |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists. |
| Copyright_xml | – notice: 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1038/s41433-024-03403-8 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1476-5454 |
| ExternalDocumentID | 39428445 |
| Genre | Journal Article |
| GroupedDBID | --- -Q- .GJ 0R~ 29G 2WC 36B 39C 3O- 4.4 406 53G 5RE 6PF 70F 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AACDK AANZL AASML AATNV AAWTL AAYZH ABAKF ABAWZ ABBRH ABCQX ABDBE ABFSG ABJNI ABLJU ABRTQ ABUWG ABZZP ACAOD ACGFS ACKTT ACPRK ACRQY ACSTC ACZOJ ADBBV AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AEZWR AFBBN AFDZB AFFNX AFHIU AFKRA AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AHWEU AIGIU AILAN AIXLP AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF AOIJS ATHPR AXYYD AYFIA BAWUL BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAG CCPQU CGR COF CS3 CUY CVF DIK DNIVK DPUIP E3Z EBLON EBS EBX ECM EE. EIF EIOEI EJD EMB EMOBN F5P FDQFY FERAY FIGPU FIZPM FSGXE FYUFA GX1 HCIFZ HMCUK HYE HZ~ IWAJR JSO JZLTJ KQ8 L7B M1P M7P NPM NQJWS O9- OK1 P2P PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q2X RNS RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TR2 UKHRP W2D ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c375t-8e3775033cd90bea34fc356a0bf1c5943a5b1624f3e749c7a13d8d00c40573a2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001336759000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1476-5454 |
| IngestDate | Thu Sep 04 17:34:15 EDT 2025 Mon Jul 21 05:59:27 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c375t-8e3775033cd90bea34fc356a0bf1c5943a5b1624f3e749c7a13d8d00c40573a2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-3548-424X 0000-0002-0910-3829 0000-0003-0563-278X 0000-0001-9995-8574 0000-0002-6062-1066 0000-0002-3967-2694 |
| PMID | 39428445 |
| PQID | 3118832948 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3118832948 pubmed_primary_39428445 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-01-01 |
| PublicationDateYYYYMMDD | 2025-01-01 |
| PublicationDate_xml | – month: 01 year: 2025 text: 2025-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Eye (London) |
| PublicationTitleAlternate | Eye (Lond) |
| PublicationYear | 2025 |
| SSID | ssj0014770 |
| Score | 2.4278934 |
| Snippet | Sympathetic overstimulation of Müller's muscle is a suggested mechanism underlying upper eyelid retraction in thyroid eye disease (TED). We examined the effect... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 175 |
| SubjectTerms | Administration, Oral Adrenergic alpha-1 Receptor Antagonists - therapeutic use Adult Aged Eyelid Diseases - drug therapy Eyelid Diseases - etiology Eyelid Diseases - physiopathology Eyelids - drug effects Female Graves Ophthalmopathy - complications Graves Ophthalmopathy - drug therapy Graves Ophthalmopathy - physiopathology Humans Male Middle Aged Pilot Projects Prospective Studies Tamsulosin - therapeutic use |
| Title | Alpha-1 antagonist treatment for eyelid retraction in patients with thyroid eye disease-a prospective pilot study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39428445 https://www.proquest.com/docview/3118832948 |
| Volume | 39 |
| WOSCitedRecordID | wos001336759000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSyQxEA66I-JldX2tTyJ4Daa7kklyEhHFgzN4kGVuQzqPZUC6Z6ZHwX-_lZ6MnhYELx0a0hAq1cmX-lL1EXLplQcvDWe-0pGJykmmK3yVQdiiLF0BXd7an0c1HOrRyDzlgFubr1Wu1sRuofaNSzHyK0AkjN5nhL6ezlhSjUrsapbQWCc9QCiTvFqNPlkEoTqxOGz7DJGCyEkzHPRVKxAoJAZTMA6CA9P_h5jdVnO__d1B7pCfGWTSm6VX_CJrod4lm4NMo--R2U3KsGUFRbPav00qnks_bpxThLE0vIeXiafzsJgvMx_opKa5BmtLU_CW4gzPG-yDXWmmeZilOOBV8iadTl6aBe0K2O6T5_u759sHlrUXmAMlF0wHUB3F6bzhVbAgogPZt7yKhZNGgJVV0S9FhKCEccoW4LXn3CUACLY8ID_qpg6_CbVVn4OLsYzOCFPqCg-U3kdpjJAgVTwiFytbjtG1E19h69C8tuNPax6Rw-WEjKfLGhxjMHhuEkIef-HrE7JVJtXeLnBySnoRf-xwRjbc22LSzs87n8Hn8GnwDy3XzGw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Alpha-1+antagonist+treatment+for+eyelid+retraction+in+patients+with+thyroid+eye+disease-a+prospective+pilot+study&rft.jtitle=Eye+%28London%29&rft.au=Arnon%2C+Roee&rft.au=Goldberg%2C+Hila&rft.au=Ben-Simon%2C+Guy+J&rft.au=Priel%2C+Ayelet&rft.date=2025-01-01&rft.eissn=1476-5454&rft.volume=39&rft.issue=1&rft.spage=175&rft_id=info:doi/10.1038%2Fs41433-024-03403-8&rft_id=info%3Apmid%2F39428445&rft_id=info%3Apmid%2F39428445&rft.externalDocID=39428445 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-5454&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-5454&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-5454&client=summon |